For research use only. Not for therapeutic Use.
Fasnall is a selective fatty acid synthase (FASN) inhibitor with an IC50 of 3.71 μM. Fasnall induces apoptosis in HER2+ breast cancer cell lines. Fasnall shows potent anti-tumor activities[1].
Fasnall potently blocks both acetate and glucose incorporation into total lipids, with IC50 values of 147 and 213 nM, respectively, in HepG2 cells[1].
Fasnall (50 μM; 24-120 h) inhibits proliferation in breast cancer cell lines[1].
Fasnall (25-100 μM; 24 h) induces apoptosis in HER2+ breast cancer cell lines[1].
Fasnall (15 mg/kg, intraperitoneally, twice weekly; 3 weeks) shows potent anti-tumor activity in MMTV-Neu model of HER2+ breast cancer[1].
| Catalog Number | I011903 |
| CAS Number | 929978-58-5 |
| Synonyms | N-(1-benzylpyrrolidin-3-yl)-5,6-dimethylthieno[2,3-d]pyrimidin-4-amine |
| Molecular Formula | C19H22N4S |
| Purity | ≥95% |
| InChI | InChI=1S/C19H22N4S/c1-13-14(2)24-19-17(13)18(20-12-21-19)22-16-8-9-23(11-16)10-15-6-4-3-5-7-15/h3-7,12,16H,8-11H2,1-2H3,(H,20,21,22) |
| InChIKey | VSXRMURGJRAOCU-UHFFFAOYSA-N |
| SMILES | CC1=C(SC2=NC=NC(=C12)NC3CCN(C3)CC4=CC=CC=C4)C |
| Reference | [1]. Yazan Alwarawrah, et al. Fasnall, a Selective FASN Inhibitor, Shows Potent Anti-tumor Activity in the MMTV-Neu Model of HER2(+) Breast Cancer. Cell Chem Biol. 2016 Jun 23;23(6):678-88. |
